News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Ananda Developments says cannabinoid-based medicine will become "completely ubiquitous"

Ananda Developments Plc

Ananda Developments (AQSE:ANA) co-founder and CEO Melissa Sturgess visits the Proactive London studio to speak with Thomas Warner about the work the cannabinoid medicine development company is doing to help develop treatments for patients suffering from complex, chronic inflammatory pain conditions. Sturgess says that cannabinoid-based medicine will ultimately become "completely ubiquitous" and highlights the various fronts that Ananda is currently pushing forward on, including two upcoming phase II randomised controlled clinical trials. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 14, 2023 03:46 AM Eastern Daylight Time

Video
Article thumbnail News Release

Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update

Context Therapeutics

Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other CLDN6-targeted clinical candidates. Lehr says CLDN6 is differentially expressed on cancer cells with no or very low expression in normal, healthy adult tissue. CLDN6-enriched cancers include non-small cell lung (NSCLC), ovarian, testicular, and others. CTIM-76 is currently in preclinical development and is intended to direct activated immune T cells to CLDN6-expressing cancer cells. Preclinical studies of evaluating CTIM-76 demonstrates selective immune-mediated cell death of CLDN6-positive cancer cells. Contact Details Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 13, 2023 01:34 PM Eastern Daylight Time

Video
Article thumbnail News Release

Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

Theralase Technologies Inc.

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma In-Situ with a patented investigational study drug Ruvidar, subsequently activated by a proprietary investigational study laser system equipped with fiber-optic light emitters and detectors. DuMoulin-White discussed more about the study and what the interim data is telling them about the study. He also talked about the company and the other vertical it has with its Cool Laser Therapy which is focused on the research, development, production and distribution of medical laser technologies for healing pain. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 13, 2023 01:30 PM Eastern Daylight Time

Video
Article thumbnail News Release

Roberts and Ryan, Inc. Honors Laura Chan, Commander – Strategic Sealift Officer, U.S. Navy Reserves

Roberts & Ryan Investments, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned Broker Dealer, is proud to recognize Laura Chan for achieving the rank of Commander – as a Strategic Sealift Officer, U.S. Navy Reserves. On Tuesday, May 23, the Chief of Navy Reserve, Vice Admiral John Mustin, conducted her pinning ceremony at the New York Stock Exchange. Ms. Chan was accompanied by her close family, friends, and colleagues. “I’m very thankful for the village I have to support me in all of my endeavors,” said Ms. Chan. Ms. Chan has a 15+ year career in the U.S. Navy. Her last deployment was in support of Commander, U.S. 7th Fleet at Military Sealift Command (MSC) Far East as the Operational Support Officer located in Singapore. She is currently Vice President of Business Development at Roberts & Ryan, Inc., focusing on Equity Capital Markets, Pension Funds, and Corporate Development. She holds Series 7 & 63 licenses. “As of April 2023, the U.S. Navy Reserves contains 93,963 reservists that support commands located all over the world. Of the 93,000+ reservists, only 19 were selected to CDR in the Strategic Sealift Officer community and we're thrilled to have Laura as one of the 19 chosen,” said James McDevitt, Head of Equities Sales & Trading, Capital Markets at Roberts & Ryan, Inc. “Laura began her career at Roberts & Ryan as an intern in 2020, and she is one of the best examples of success in our social mission to help veterans in the area of career development. In the years since, she has proven herself to be a valuable member of our team. Her promotion to Commander is just one illustration of her dedication and work ethic, and I am proud to celebrate her accomplishment,” said Edward D’Alessandro, Chief Executive Officer of Roberts & Ryan, Inc. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.7 million dollars in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

June 13, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

BullFrog AI revolutionizing precision medicine through artificial intelligence on bfLEAP platform

BullFrog AI

BullFrog AI CEO Vin Singh joins Natalie Stoberman from the Proactive newsroom to share how the company is using artificial intelligence (AI) for drug development through a renewed collaboration with Johns Hopkins Applied Physics Laboratory. Singh says BullFrog AI aims to reduce the time, costs, and risks associated with drug development by leveraging their bfLEAP proprietary AI platform. Singh explains the platform can identify new drug targets, provide insights, and help stratify patients for clinical trials in order increase the chances of success. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

June 12, 2023 01:51 PM Eastern Daylight Time

Video
Article thumbnail News Release

Father Boyle to Speak at The Chicago School’s SoCal Commencement

The Chicago School of Professional Psychology

Father Gregory Boyle, who has championed rehabilitation of former Los Angeles gang members for more than three decades, will be keynote speaker at The Chicago School of Professional Psychology’s Southern California commencement ceremony June 9, 2023 at the Long Beach Convention Center’s Terrace Theater. In recognition of his groundbreaking work educating, employing, and inspiring thousands of troubled youth and young adults, President Dr. Michele Nealon, Psy.D., will award Rev. Boyle a Doctor of Humane Letters, Honoris Causa. “We are honored to have Father Boyle speak to our 275 graduates about his life’s work rehabilitating individuals whom society have shunned,” said Dr. Nealon. “Father Boyle is the rare visionary who is passionate and practical—someone who is able to find solutions to what appear to be intractable problems.” Rev. Boyle was originally scheduled to speak at the 2020 commencement, which was cancelled due to the pandemic lockdown. Named a “Champion of Change” by former President Barack Obama in 2014, Rev. Boyle has been widely honored for his work, including receiving the Laetare Medal, the oldest honor given to American Catholics. A Los Angeles native, Rev. Boyle entered the Society of Jesus (Jesuits) immediately after graduating from Loyola High School in 1972. Over the next dozen years, he earned a bachelor's degree in English from Gonzaga University; a master’s in English from Loyola Marymount University; a Master of Divinity from the Weston School of Theology; and a Master of Sacred Theology from the Jesuit School of Theology, now part of Santa Clara University. From 1986 to 1992 Rev. Boyle served as pastor of Dolores Mission Church in Boyle Heights, Where he witnessed the devastating impact of gang violence during the “decade of death” that began in the late 1980s and peaked at 1,000 gang-related killings in 1992. In the face of law enforcement tactics and criminal justice policies of suppression and mass incarceration as the means to end gang violence, he and parish and community members adopted what was a radical approach at the time: treat gang members as human beings. In 1988 Rev. Boyle started what would eventually become Homeboy Industries, which employs and trains former gang members in a range of social enterprises. Homeboy now supports around 10,000 men and women a year, offering therapy, classes, services, job training, and employment at Homeboy Bakery, Homegirl Café, or Homeboy Silkscreen & Embroidery. At the center of it all is founder Rev. Boyle, who describes his work as “radical kinship,” accompanying those who come through Homeboy at virtually every step of their journeys at Homeboy and beyond. Rev. Boyle is the author of the 2010 New York Times -bestseller Tattoos on the Heart: The Power of Boundless Compassion. Other books he has written include Barking to the Choir: The Power of Radical Kinship, and The Whole Language: The Power of Extravagant Tenderness. “We are all invited into this exquisite mutuality where there is no us and them,” Rev. Boyle said. “Once we know that we are unshakably good and that we belong to each other, we can roll up our sleeves … and create anew this place of love and belonging that God would recognize.” About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

June 08, 2023 12:00 PM Pacific Daylight Time

Article thumbnail News Release

AccuStem Sciences agrees to joint collaboration with University Hospitals

AccuStem

AccuStem Sciences Inc CEO Wendy Blosser joined Steve Darling from Proactive to share more details about the company that started as a spinout of Tiziana Life Sciences to focus on three primary healthcare verticals including pharmaceuticals, diagnostics or devices. The company’s main product is StemPrintER which is a 20-gene test using stem cells to predict cancer recurrence. Blosser telling Proactive more about the technology and where they see the biggest opportunities. One of those is a recent announcement that saw the company agree to a joint clinical collaboration agreement with University Hospitals. She says that agreement will provide tissue samples with clinical outcomes to AccuStem for research purposes. The agreement covers different cancers but will initially focus on breast cancer. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 08, 2023 02:10 PM Eastern Daylight Time

Video
Article thumbnail News Release

Voyageur Pharmaceuticals shares successful environmental assessment for minerals subsidiary

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals CEO Brent Willis joins Natalie Stoberman from the Proactive studios to discuss the successful completion of environmental and geotechnical field work assessment at its Frances Creek project site through its 100% owned subsidiary Voyageur Industrial Minerals. Willis says this milestone allows Voyageur Pharmaceuticals to mine and quarry their own minerals for their drugs, resulting in reduced costs and competitive pricing. Willis adds this milestone signifies progress towards production and positions Voyageur's Industrial Minerals division to compete effectively in the market. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 08, 2023 01:32 PM Eastern Daylight Time

Video
Article thumbnail News Release

Evgen Pharma "very busy" at start of "exciting year"

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones speaks to Proactive from the sidelines of the BIO International Convention in Boston, MA, following the release of final results for the year to 31st March 2023. Dr Jones gives his take on how the business performed over the twelve months, before moving on to talk about what the current year has in store. He says the clinical stage drug development company is "very busy" at the start of an "exciting year." He also thanks outgoing chief financial officer Richard Moulsen for his contribution to the company. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 08, 2023 04:13 AM Eastern Daylight Time

Video
1 ... 115116117118119 ... 302